Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
Endogenous anxiety (anxiety hysteria, agoraphobia with panic attacks) is characterized by sudden, spontaneous panic attacks accompanied by multiple autonomic symptoms, overwhelming fear, a flight response, and polyphobic behavior. Psychotherapy, behavior therapy, and tranquillizers have been of limited success in treating this syndrome. Fifty-seven patients severely disabled by the syndrome for a mean period of 13 years completed the three-month study. Randomly assigned in a double-blind, placebo-controlled design to imipramine hydrochloride, pheneizine sulfate, or placebo, they were seen in supportive group therapy every two weeks. Patients in the pheneizine and imipramine cells showed significant improvement ovehe persistent trend for pheneizine to be superior to imipramine achieved significance only on the Work and Social Disability Scale and the Sympton Severity and Phobic Avoidance Scale. The implications for classification and theory are discussed.
D000328:Adult; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D003863:Depression / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006998:Hypochondriasis / Q000188:drug therapy* / Q000523:psychology; D007046:Hysteria / Q000188:drug therapy* / Q000523:psychology; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D010624:Phenelzine / Q000627:therapeutic use; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology; D011615:Psychotherapy, Group; D012008:Recurrence; D012917:Social Adjustment
D010624:Phenelzine; D007099:Imipramine